ArticleAmerican journal of cancer research2025
Novel therapeutic agents and intensive chemotherapy improve survival outcomes in patients with mantle cell lymphoma.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mantle cell lymphoma (MCL) is a rare type of mature B-cell lymphoma. This multicenter retrospective cohort study aimed to analyze the epidemiological characteristics, treatment patterns, and survival outcomes of patients with MCL in Taiwan. We collected baseline information, treatment modalities, and response evaluation of patients with MCL. A total of 204 patients who were diagnosed with mantle cell lymphoma between November 2001 and July 2022 were included. When divided into low, intermediate, and high-risk groups according to the Mantle Cell Lymphoma International Prognostic Index, their median overall survival times were 83.7 (95% confidence interval [CI]: 77.7-NR), 72.7 (95% CI: 30.7-NR), and 19.3 (95% CI: 14.2-45.6) months, respectively. In this multicenter retrospective cohort, first line rituximab containing regimens, higher chemotherapy intensity, and ASCT were associated with longer PFS/OS, although the magnitude and statistical significance varied after adjustment and by transplant eligibility. Given potential confounding by indication, era effects, and missing data, these findings should be interpreted as observational associations rather than causal effects. Prospective or target trial emulation studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.